- Izotropic (IZO) unveils commercial prototype device design, files new patents
- IzoView has been upgraded and reengineered to deliver a state-of-the-art breast imaging device for the future
- A key feature of IzoView’s design is the development of self-shielding, which results in radiation emitted during imaging being contained within the device itself
- As its first self-shielded design, only the patient’s breast being imaged is exposed to radiation
- The company has begun filing patents to protect unique and important features of the IzoView Breast CT System
- Izotropic Corporation (IZO) is up 3.08 per cent, trading at C$0.67 at 12:22 pm ET
Izotropic (IZO) has unveiled the commercial prototype device design that will be used in forthcoming clinical studies for market authorization in the U.S.
IzoView has been upgraded and reengineered to deliver a state-of-the-art breast imaging device for the future.
The experience and importance for patients, operators, insurance providers, and customers have been further studied in recent months to yield what the company believes is a design and functionality that, once approved for sale, will drive demand, acceptance, and market uptake.
A key feature of IzoView’s design is the development of self-shielding, which results in radiation emitted during imaging being contained within the device itself, protecting the operator and surrounding physical areas.
As its first self-shielded design, only the patient’s breast being imaged is exposed to radiation.
IzoView can be safely operated in a space where protective barriers and lead partitions commonly used for CT imaging devices to protect the operator and surrounding area from radiation exposure are not always required.
The company has begun filing patents to protect unique and important features of the IzoView Breast CT System.
Izotropic will co-own these patents with The Regents of the University of California, from which Izotropic has the exclusive worldwide licensing rights to Breast CT, including ten other patents and ongoing patent applications.
Izotropic Corporation is the only publicly-traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers.
To expedite patient and provider access to IzoView, Izotropic’s initial clinical study intends to demonstrate the superior performance of diagnostic breast CT imaging over diagnostic mammography procedures.
Izotropic Corporation (IZO) is up 3.08 per cent, trading at C$0.67 at 12:22 pm ET.
